article thumbnail

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

You just want to slash it, rip it out or attack it like an enemy target,” said Benjamin Zeskind, co-founder, CEO and president of Immuneering Corporation. To overcome that hurdle, Immuneering is testing an approach that slows cancer down rather than rushing to destroy it.

article thumbnail

Pharmacists Bridge the Gaps in Care Transitions

Pharmacy Times

February 2013. BMC Health Serv Res. 2024;24(1):576. doi:10.1186/s12913-024-11047-3 5. American Society of Health-System Pharmacists and American Pharmacists Association. ASHP-APhA Medication Management in Care Transitions Best Practices. Accessed July 7, 2025. Tasseff N, Axtell S, Nixon B. Accessed July 7, 2025.[link]

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Dive

in 2013 — the field has taken off since the success of Novartis’ prostate cancer treatment Pluvicto. It’s a way to dismantle a critical barrier to immune and therapeutic access,” he wrote in an email to BioPharma Dive. The technology works by attaching a radioisotope to a targeting compound via a specially engineered “linker” molecule.

article thumbnail

Lumateperone Submits Application for Schizophrenia Indication to FDA for Supplemental New Drug

Pharmacy Times

Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. International Clinical Psychopharmacology, 31 (4), 202–209. Lafeuille, M. Lefebvre, P., Fastenau, J., Doshi, D., & & Duh, M. Journal of Medical Economics, 16 (11), 1290–1299.

article thumbnail

Steroid Use During ICI Treatment Lessens Effectiveness in Patients With NSCLC

Pharmacy Times

SHOW MORE Steroids hindered the shrinkage of tumors in patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) therapy. A total of 277 patients (median age: 66 years; range: 30–89 years) with NSCLC who initiated treatment between October 2013 and August 2023 were enrolled. months) and 6.4

article thumbnail

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

Touchstone Books; 2013. Time Enough for Love. Putnam’s Sons; 1973. Hyperbole and a Half: Unfortunate Situations, Flawed Coping Mechanisms, Mayhem, and Other Things That Happened. Rao KV, Gulbis AM, Mahmoudjafari Z. 2022;5(11):1112-1120. doi:10.1002/jac5.1693 4. 6 challenges facing community oncology practices.

article thumbnail

IBI303, Humira Biosimilar, Shows Comparable Efficacy and Cost Benefit to Reference Product

Pharmacy Times

1 In 2013, Humira was approved in China as a treatment for ankylosing spondylitis, a chronic inflammatory disease that causes axial arthritis and often results in inflammatory lower back pain early in the disease’s course.